reports
CytoSorbents Postpones Earnings Release to Allow More Time to Complete...
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025 PRINCETON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it is postponing its pr...
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Res...
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year 2024 financial results and recent business highlights after the market close on Thursday, March 6, 2025. CytoSorbents’ management will host a live conference call, presentation webcast, and a question-and-answer session starting at 4:30 PM ET the sa...
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previo...
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants 1,417,208 Series A Right Warrants Exercised at $1.13 Per Share, Providing $1.6 Million in Aggregate Gross Proceeds PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today the Company received aggregate gross proceeds of $1.6 million from the exercise of 1,417,208 Series A Right Warrants at $1.13 per warrant upon their expira...
- Jonathan Moreland
XNCR XENCOR INC.
RLI RLI CORP.
PBF PBF ENERGY INC. CLASS A
ORRF ORRSTOWN FINANCIAL SERVICES INC.
NEOG NEOGEN CORPORATION
MKL MARKEL CORPORATION
LAKE LAKELAND INDUSTRIES INC.
JBLU JETBLUE AIRWAYS CORPORATION
EL ESTEE LAUDER COMPANIES INC. CLASS A
CTSO CYTOSORBENTS
BUSE FIRST BUSEY CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
CBFV CB FINANCIAL SERVICES INC.
MUR MURPHY OIL CORPORATION
OLN OLIN CORPORATION
WVE WAVE LIFE SCIENCES
OVLY OAK VALLEY BANCORP
FLWS 1-800-FLOWERS.COM CL A
KALV KALVISTA PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
MPB MID PENN BANCORP INC.
CIK CREDIT SUISSE ASSET MANAGEMENT INCOME FUND INC.
COGT COGINT
NWFL INC.
FRAF NORWOOD FINANCIAL CORP.
ETST FRANKLIN FINANCIAL SERVICES CO.
LOOP EARTH SCIENCE TECH
ANIX LOOP INDUSTRIES
MFON ANIXA BIOSCIENCES
PNTG MOBIVITY HOLDINGS CORP.
ZYME PENNANT GROUP
PLCE ZYMEWORKS INC.
ALLY THE CHILDREN'S PLACE RETAIL STORES
IMNM INC.
CTOS GMAC LLC
IBRX IMMUNOME
BHRB CUSTOM TRUCK ONE SOURCE
VGAS INC.
TLSI IMMUNITYBIO INC
TKO BURKE & HERBERT BANK & TR/VA
PCSA VERDE CLEAN FUELS INC
PROP TRISALUS LIFE SCIENCES INC
MIO TKO GROUP HOLDINGS
MXF INC.
SUNS PROCESSA PHARMACEUTICALS INC
BATRK PRAIRIE OPERATING CO.
MYCB PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
THE MEXICO FUND
INC.
SUNRISE REALTY TRUST
LIBERTY MEDIA CORPORATION
MY CITY BUILDERS
INC.
- Jonathan Moreland
RLI RLI CORP.
NEOG NEOGEN CORPORATION
LNDC LANDEC CORP.
LAKE LAKELAND INDUSTRIES INC.
CTSO CYTOSORBENTS
ASA ASA
WVE WAVE LIFE SCIENCES
OVLY OAK VALLEY BANCORP
FLWS 1-800-FLOWERS.COM CL A
FBK FB FINANCIAL CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ESQ ESQUIRE FINANCIAL HOLDINGS
MPB MID PENN BANCORP INC.
CIK CREDIT SUISSE ASSET MANAGEMENT INCOME FUND INC.
COGT COGINT
ETST INC.
LOOP EARTH SCIENCE TECH
FUND LOOP INDUSTRIES
ANIX ROYCE FOCUS TRUST
LBSRD INC.
ETON ANIXA BIOSCIENCES
GRX LIBERTY STAR URANIUM & METALS
MFON ETON PHARMACEUTICALS
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ZYME MOBIVITY HOLDINGS CORP.
ALLY PENNANT GROUP
ENX ZYMEWORKS INC.
IBRX GMAC LLC
ACXP EATON VANCE NEW YORK MUNICIPAL BOND FUND
CVI IMMUNITYBIO INC
TLSI ACURX PHARMACEUTICALS INC
PCSA CVR ENERGY
PROP INC.
AVDL TRISALUS LIFE SCIENCES INC
MIO PROCESSA PHARMACEUTICALS INC
MXF PRAIRIE OPERATING CO.
SUNS AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
TXO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
AMST THE MEXICO FUND
WHLM INC.
IBIO SUNRISE REALTY TRUST
SDHY MORNINGSTAR PARTNERS
BATRK L.P.
MYCB AMESITE INC.
WILHELMINA INTERNATIONAL INC
IBIO INC.
PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
LIBERTY MEDIA CORPORATION
MY CITY BUILDERS
INC.
- Jonathan Moreland
OPK OPKO HEALTH INC.
NEOG NEOGEN CORPORATION
LNDC LANDEC CORP.
LAKE LAKELAND INDUSTRIES INC.
CTSO CYTOSORBENTS
FRD FRIEDMAN INDUSTRIES INC.
ESQ ESQUIRE FINANCIAL HOLDINGS
MPB MID PENN BANCORP INC.
ETST EARTH SCIENCE TECH
ANIX ANIXA BIOSCIENCES
LBSRD LIBERTY STAR URANIUM & METALS
ALLY GMAC LLC
ACXP ACURX PHARMACEUTICALS INC
GLSI GREENWICH LIFESCIENCES INC
TLSI TRISALUS LIFE SCIENCES INC
PCSA PROCESSA PHARMACEUTICALS INC
MXF THE MEXICO FUND
AMST INC.
MYCB AMESITE INC.
MY CITY BUILDERS
INC.
- Jonathan Moreland
NEOG NEOGEN CORPORATION
LAKE LAKELAND INDUSTRIES INC.
CTSO CYTOSORBENTS
CDXS CODEXIS
ASA ASA
ADC AGREE REALTY CORPORATION
WVE WAVE LIFE SCIENCES
FBK FB FINANCIAL CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
CIK CREDIT SUISSE ASSET MANAGEMENT INCOME FUND INC.
COGT COGINT
ZIVO INC.
ETST ZIVO BIOSCIENCE
FUND INC.
ANIX EARTH SCIENCE TECH
LBSRD ROYCE FOCUS TRUST
ETON INC.
GRX ANIXA BIOSCIENCES
MCFT LIBERTY STAR URANIUM & METALS
PGNY ETON PHARMACEUTICALS
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
DCTH MASTERCRAFT BOAT HOLDINGS
ENX PROGYNY
PRLD PENNANT GROUP
NVCT DELCATH SYSTEMS
ANEB EATON VANCE NEW YORK MUNICIPAL BOND FUND
IBRX PRELUDE THERAPEUTICS
BHVN NUVECTIS PHARMA INC
ACXP ANEBULO PHARMACEUTICALS INC
BUKS IMMUNITYBIO INC
GLSI BIOHAVEN LTD
MEGI ACURX PHARMACEUTICALS INC
CVI BUTLER NATIONAL CORP
SRFM GREENWICH LIFESCIENCES INC
OCX MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
AVDL CVR ENERGY
MXF INC.
TXO SURF AIR MOBILITY INC.
TTGT ONCOCYTE CORPORATION
AMST AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
WHLM THE MEXICO FUND
IBIO INC.
SDHY MORNINGSTAR PARTNERS
BATRK L.P.
MYCB TECHTARGET INC.
AMESITE INC.
WILHELMINA INTERNATIONAL INC
IBIO INC.
PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
LIBERTY MEDIA CORPORATION
MY CITY BUILDERS
INC.
- Jonathan Moreland
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed ...
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering Oversubscribed Rights Offering Generated $6.25 Million in Aggregate Gross Proceeds Offering Proceeds Satisfies Debt Covenant, Unlocking $5.0 Million in Restricted Cash Currently on the Balance Sheet PRINCETON, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that the Company closed the subscription period of its previously announced rights offering (t...
CytoSorbents Expands Global Footprint with Opening of New Regional Sal...
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai PRINCETON, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the opening of a new regional sales subsidiary in Dubai, United Arab Emirates (UAE). The new subsidiary provides a gateway into the Middle East and Africa - regions with increasing demand for advanced medical technologies and high-quality therapies in critical care and cardiac surgery. ...
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Yea...
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor meetings in San Francisco during J.P. Morgan Healthcare Conference week PRINCETON, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, toda...
CytoSorbents Rights Offering Begins
CytoSorbents Rights Offering Begins To Participate, Eligible Stockholders Should Consult Their Broker or Financial Advisor in Advance of the Rights Offering Expiration on January 10, 2025 PRINCETON, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO) announces the commencement of its Rights Offering, previously detailed in our . Stockholders and certain Warrantholders of record on December 16, 2024 are now being distributed a dividend of one non-transferable Subscription Right Warrant (“Subscription Right”) for each share of common stock owned on the record date. Each Subscrip...
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Mo...
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week PRINCETON, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that management will host in-person investors meetings in San Francisco alongside the 43rd Annual J.P. Morgan Healthcare Conference being held January 13-15, 2025, in San Francisco, CA. is coordinating meetings on the Company’s behalf. To schedule a meeting with Dr. Ph...
CytoSorbents Announces Rights Offering
CytoSorbents Announces Rights Offering Investors Must Hold or Buy CTSO Common Stock by Close of Nasdaq Trading on Friday, December 13, 2024 to Participate PRINCETON, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the details of its anticipated Rights Offering. Investors who hold or have bought CTSO stock at the close of Nasdaq trading on Friday, December 13, 2024 will be deemed stockholders of record on December 16, 2024 and...
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcar...
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that management will participate at the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024, in New York, NY. Dr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer, will participate in one-on-one investor meetings on Wednesday, Dece...
CytoSorbents And Converge Biotech Announce Strategic Partnership to Ex...
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and , a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in ...
CytoSorbents Reports Third Quarter 2024 Financial and Operational Resu...
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported unaudited financial and operating results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Product revenue of $8.6 million, 11% growth versus $7.8 million in Q3 2023Total revenue of $9.4 million inclusive of product and grant revenue, 7% growth versus $8.8 mill...
CytoSorbents Submits Health Canada Medical Device License Application ...
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification Targets the reduction in CABG-related bleeding severity due to the blood thinning drug, ticagrelor – a major unmet medical need in heart attack patients requiring surgerySuccessful MDSAP certification confirms compliance with Health Canada and U.S. FDA quality management system requirements, replacing FDA audit and inspection if requiredHealth Canada and U.S. FDA regulatory decisions expected in 2025 PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a lea...
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of...
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025 PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the U.S. Food and Drug Administration (FDA) has accepted its De Novo medical device application for DrugSorb™-ATR and ini...
CytoSorbents to Report Third Quarter 2024 Operating and Financial Resu...
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results PRINCETON, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2024 operating and financial results after the market close on Thursday, November 7, 2024. CytoSorbents’ management will host a live conference call, presentation webcast, and a question-and-answer session starting at 4:30PM ET the same day. Webcast Details:Date: Thursday, November 7, 2024Tim...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.